Dipna Pharmachem

Which are the latest news on Dipna Pharmachem?

Why is Dipna Pharmachem Ltd falling/rising?

As of 05-Sep, Dipna Pharmachem Ltd's stock price is at 5.51, down 5.0% after a trend reversal. Despite recent positive returns, the stock has significantly underperformed its sector and shows a bearish long-term trend.

As of 05-Sep, Dipna Pharmachem Ltd's stock price is falling, currently at 5.51, which reflects a decrease of 0.29 or 5.0%. This decline follows a trend reversal after three consecutive days of gains. The stock has underperformed its sector by 4.55% today, indicating that it is not keeping pace with its peers. Additionally, the stock's delivery volume has decreased significantly, falling by 43.75% compared to the 5-day average, suggesting reduced investor participation. <BR><BR>While the stock has shown positive returns over the past week and month, with increases of 3.77% and 32.13% respectively, its year-to-date performance remains unreported, and it has experienced a substantial decline of 72.64% over the past year. The current price is higher than the 5-day moving average but lower than the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend in the longer term. Overall, these factors contribute to the current decline in the stock's price.

Who are in the management team of Dipna Pharmachem?

The management team of Dipna Pharmachem includes Keyur Shah (Managing Director), Dipna Shah (Director), Nandish Jani, Chinu Kalal, and Jitendra Parmar (Independent Directors), along with Khushboo Jethaliya and Madhuri Gurwani (Company Secretaries & Compliance Officers). They oversee operations and ensure regulatory compliance.

The management team of Dipna Pharmachem includes the following individuals:<BR><BR>1. Keyur Shah - Managing Director<BR>2. Dipna Shah - Director<BR>3. Nandish Jani - Independent Director<BR>4. Chinu Kalal - Independent Director<BR>5. Khushboo Jethaliya - Company Secretary & Compliance Officer<BR>6. Jitendra Parmar - Independent Director<BR>7. Madhuri Gurwani - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and ensuring compliance with regulatory requirements.

What does Dipna Pharmachem do?

Dipna Pharmachem Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2011 and converted to a public company in 2022. As of March 2026, it reported net sales of 2 Cr and a market cap of INR 14 Cr, with a P/E ratio of 5.00.

Overview:<BR>Dipna Pharmachem Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in 2011 and underwent a name change from Dipan Pharmachem Private Limited to Dipna Pharmachem Private Limited in 2012. It was later converted from a Private Limited to a Public Limited company in 2022. The latest quarterly results report net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 14 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 5.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.44<BR>- Return on Equity: 6.83%<BR>- Price to Book: 0.36<BR><BR>Contact Details:<BR>No Company Details Available. Registrar Address: Not available.

Who are the peers of the Dipna Pharmachem?

Dipna Pharmachem's peers include Bacil Pharma, Zenith Health, Desh Rakshak, and others, with Unjha Formul. showing the highest 1-year return at 10.70% and Dipna Pharmachem the lowest at -73.42%. Management risks vary, with several peers rated below average.

Peers: The peers of Dipna Pharmachem are Bacil Pharma, Zenith Health, Desh Rakshak, Starsource Multi, Ortin Global, Unjha Formul., Beryl Drugs, Mono Pharmacare, and Saroja Pharma In.<BR><BR>Quality Snapshot: Excellent growth is observed at Dipna Pharmachem, while Below Average management risk is found at Zenith Health, Desh Rakshak, Ortin Global, Beryl Drugs, Mono Pharmacare, and the rest. Average management risk is noted at Unjha Formul. and Saroja Pharma In. The Capital Structure is rated Good for Zenith Health and Unjha Formul., while Below Average is seen at Dipna Pharmachem, Desh Rakshak, Ortin Global, Beryl Drugs, Mono Pharmacare, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Unjha Formul. at 10.70%, while the lowest is Dipna Pharmachem at -73.42%. Dipna Pharmachem's 1-year return is significantly lower than that of its peers. Additionally, Bacil Pharma, Desh Rakshak, and Saroja Pharma In have negative six-month returns.

How big is Dipna Pharmachem?

As of 31st August, Dipna Pharmachem Ltd has a market capitalization of 14.00 Cr, with net sales of 71.46 Cr and net profit of 1.72 Cr over the latest three quarters. Shareholder's funds are 38.49 Cr, and total assets amount to 132.38 Cr as of March 2025.

As of 31st August, Dipna Pharmachem Ltd has a market capitalization of 14.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest quarterly performance, the sum of Net Sales for the latest three quarters is 71.46 Cr, while the sum of Net Profit for the same period is 1.72 Cr.<BR><BR>The reporting period for the balance sheet snapshot is March 2025. Shareholder's Funds stand at 38.49 Cr, and Total Assets amount to 132.38 Cr.

When is the next results date for Dipna Pharmachem Ltd?

The next results date for Dipna Pharmachem Ltd is July 2, 2026.

The next results date for Dipna Pharmachem Ltd is scheduled for July 2, 2026.

How has been the historical performance of Dipna Pharmachem?

Dipna Pharmachem has experienced a significant decline in financial performance, with net sales dropping from 727.56 Cr in March 2022 to 124.92 Cr by March 2025, alongside decreasing operating profit and negative cash flow from operations. Despite stable total liabilities, the overall trend indicates ongoing challenges in profitability and sales.

Answer:<BR>The historical performance of Dipna Pharmachem shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Dipna Pharmachem's net sales peaked at 727.56 Cr in March 2022 but have since declined to 124.92 Cr by March 2025. The total operating income followed a similar trend, dropping from 727.56 Cr in March 2022 to 124.93 Cr in March 2025. The company's operating profit (PBDIT) also saw a decline from 22.10 Cr in March 2022 to 3.45 Cr in March 2025, while profit before tax remained relatively stable at 1.42 Cr in March 2025 compared to 1.42 Cr in March 2024. Profit after tax showed a slight decrease from 1.09 Cr in March 2024 to 0.97 Cr in March 2025. The company's total liabilities have remained relatively stable, with a slight decrease from 132.90 Cr in March 2024 to 132.38 Cr in March 2025. Cash flow from operating activities has been negative, with -9.00 Cr in March 2025, indicating ongoing challenges in generating cash from operations. Overall, the financial performance of Dipna Pharmachem reflects a downward trend in sales and profitability over the past few years.

Is Dipna Pharmachem overvalued or undervalued?

As of November 21, 2025, Dipna Pharmachem is considered overvalued due to a high PE ratio of 41.87 and low ROE of 2.52%, despite a strong one-year stock return of 150.22%, especially when compared to peers like Sun Pharma and Cipla.

As of 21 November 2025, Dipna Pharmachem's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued based on its high PE ratio of 41.87, an EV to EBIT ratio of 16.69, and a ROE of only 2.52%. In comparison, peers such as Sun Pharma have a PE of 36.98 and an EV to EBITDA of 24.43, while Cipla, which is rated attractive, has a significantly lower PE of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Given these ratios and the peer comparison, Dipna Pharmachem appears to be overvalued in the current market context. Despite a strong one-year stock return of 150.22%, which outperformed the Sensex's 10.47%, the company's financial metrics suggest that its stock price may not be justified at this level.

Who are the top shareholders of the Dipna Pharmachem?

The top shareholders of Dipna Pharmachem include promoter Keyur Dipakkumar Shah with 9.97% and public shareholder Teena Kirti Jain with 4.1%. Individual investors hold a significant 71.21% of the shares, with no institutional holdings reported.

The top shareholders of Dipna Pharmachem include Keyur Dipakkumar Shah, who is the promoter with the highest holding at 9.97%. The highest public shareholder is Teena Kirti Jain, holding 4.1%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 71.21% of the shares. There are no institutional holdings from mutual funds or foreign institutional investors.

What is the technical trend for Dipna Pharmachem?

As of June 2, 2025, Dipna Pharmachem's technical trend is mildly bullish, supported by strong weekly indicators and bullish Bollinger Bands, but tempered by mixed monthly signals and a mildly bearish outlook from Dow Theory.

As of 2 June 2025, the technical trend for Dipna Pharmachem has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The RSI shows no signal on the weekly chart and is bearish on the monthly chart, suggesting weakening momentum. Bollinger Bands are bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, Dow Theory indicates a mildly bearish trend on the weekly chart, which adds caution. Overall, the current technical stance is mildly bullish, driven by strong weekly indicators but tempered by monthly bearish signals.

Has Dipna Pharmachem declared dividend?

No Dividend History Available